High magnification chromoscopic colonoscopy as a screening tool in acromegaly

We read with great interest the paper by Jenkins et al (Gut 2002;51:V13–14) regarding screening guidelines for colorectal cancer (CRC) and polyps in patients with acromegaly and the subsequent discussion by Renehan addressing screening inconsistencies compared with other high risk groups. The optimal colorectal screening modality and frequency in this group however requires clarification. Colonoscopy in this patient group is technically demanding and often complicated by inadequate bowel preparation. However, despite current controversies regarding true CRC risk categorisation in acromegaly, previous data from the largest published series showed a trend for adenoma and carcinoma formation in the right hemi colon. This is an important observation for many reasons.

Flat adenomas and carcinomas can be difficult to detect by conventional colonoscopy alone, often presenting as subtle mucosal erythema, mucosal pallor, fold convergence, interruption of inominate grooves, air induced deformation, or loss of vascular network. The neoplastic risk for this morphologically distinct group has additionally been shown by many authors to be higher when compared with exophytic polyps and carcinoma formation in the right hemi colon. A total of 28 lesions were identified in 15 patients. Twenty two hyperplastic lesions were identified (79%) of which 17 (77%) were flat (JRSC II). Twenty (91%) were located in the left colon and rectum. Of the five adenomas identified, four (80%) were present in the right colon with 4/5 (80%) being of JRSC II morphology. A single adenoma with high grade dysplasia was present in the right colon and was flat with a small area of central depression. No invasive carcinomas were diagnosed. Results are summarised in table 1.

Table 1 Lesion demographics

<table>
<thead>
<tr>
<th>Histology</th>
<th>n</th>
<th>I</th>
<th>II</th>
<th>Dominant crypt pattern</th>
<th>Mean size (mm)</th>
<th>Anatomical location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperplastic</td>
<td>22</td>
<td>5</td>
<td>17</td>
<td>I/II</td>
<td>6</td>
<td>Rt colon</td>
</tr>
<tr>
<td>Adenoma LGD</td>
<td>5</td>
<td>1</td>
<td>4</td>
<td>III</td>
<td>6.5</td>
<td>Lt colon/rectum</td>
</tr>
<tr>
<td>Adenoma HGD</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>IV</td>
<td>5</td>
<td>Lt colon/rectum</td>
</tr>
<tr>
<td>Invasive neoplasia</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Nill</td>
<td>0</td>
<td>Lt colon/rectum</td>
</tr>
</tbody>
</table>

In our prospective study, 38 patients with acromegaly underwent total colonoscopy by a single endoscopist using the Olympus C240Z magnifying colonoscope. Preparation was with 4 litres of Creenprep 24 hours prior to the procedure. Pancolonic chromooscopy using 0.5% indigo carmine sprayed onto the colonic mucosa using an Olympus diffusion catheter (CS12890) was applied. Identified lesions were morphologically grouped according to the Japanese Research Society Classification (JRSC). A flat lesion was defined as mucosal change with a flat or rounded surface combined with a height of less than half the diameter of the lesion. High magnification views of all suspected lesions were then obtained and reported according to the modified Kudo criteria. Tissue sampling was performed with cold biopsy or endoscopic mucosal resection following exclusion of a Kudo type V(n)/IIIs invasive crypt pattern which suggests deep submucosal invasion. Mean intubation and extubation times were recorded. Neoplastic change was classified according to the Vienna criteria.
Fetal “cardiac mucosa” is not adult cardiac mucosa

De Hertogh et al’s autopsy study of the fetal gastro-oesophageal region provides valuable insight into the development of for Exit epithelium in the 13–24 week gestational period (De Hertogh 2003;52:791–6). Coincidentally, two other studies appeared on the same subject in April 2003. These studies were stimulated by our hypothesis that cardiac mucosa does not exist as a normal structure in adult life.

Three columnar epithelial types are reported between squamous epithelium and parietal cell containing gastric mucosa in De Hertogh’s study (De Hertogh 2003:52:791–6). These are: “primitive oesophageal mucosa”, “primitive stomach mucosa”, and “cardiac mucosa”. Careful anatomical correlation place all of these mucosae in the oesophagus, proximal to the gastro-oesophageal junction. “Primitive oesophageal mucosa” is a ciliated epithelium that disappears after about 24 weeks. “Proximal stomach mucosa” is a layer of flat columnar cells containing depressions that correspond to early gland pits distally. “Cardiac mucosa” is composed of foveolar and surface epithelium overlying glandular structures containing no parietal cells. The description of “cardiac mucosa” and figs 2 and 4 show a very thin columnar epithelium composed of uniform mucous cells with foveolar pits and rudimentary sac-like structures devoid of any inflammation. Derdoy et al’s “cardiac mucosa” and Park et al’s “transition zone” are identical in appearance. I have never seen this fetal epithelium in any adult patient. The fact that these authors call it “cardiac mucosa” does not make it identical to the more conventional cardiac mucosa seen in adults. The only similarity is that it is a glandular mucosa developed if present at all. I would like to propose an alternate explanation for the changes seen in all three papers that would provide a better explanation of the data in the papers. The early fetal oesophagus is lined by primitive undifferentiated ciliated columnar epithelium. It begins differentiating into squamous epithelium proximally and gastric mucosa distally. Gastric differentiation is marked by the appearance of true glands containing parietal cells. In the second trimester, the oesophageal squamous epithelium is separated from the remaining gastric mucosa by a columnar epithelium composed of forgoing columnar stem cells forming a flat surface and a foveolar pit. This is uncommitted fetal columnar epithelium. This continues to develop into either squamous epithelium proximally or parietal cell containing gastric mucosa distally, so that its overall length decreases as fetal age increases (as shown in De Hertogh et al and Derdoy et al’s studies). With completion of the development of the lower oesophageal sphincter in early infant life, the physiological gastro-oesophageal junction is defined and the uncommitted columnar forgoing epithelium completes its mucous layer and squamous in the oesophagus and gastric mucosa with parietal cells distal to the lower oesophageal sphincter. The uncommitted forgoing columnar epithelium disappears. The only normal mucosa seen after development is complete are squamous and gastric with parietal cells. This is proven by illustrations that show children with a direct transition of squamous epithelium to gastric mucosa with parietal cells (Chandrasoma 1974:430–5). Obviously, our work is not completely representative of the development of the gastro-oesophageal region throughout gestation. Notably, we need extra specimens from third trimester fetuses. At this moment we are gathering this material for future research. As Dr Chandrasoma himself says, the most important reason for the divergent conclusions of his work and ours are the terminology and interpretation of the data. What we call CM, in Dr Chandrasoma’s opinion, is uncommitted epithelium devoid of glands. He specifically warns against applying the designation “gland” to the tangentially cut tortuous ends of the foveolar pits (our fig 2 and fig 4). We believe glands are present in these illustrations. We formed this conclusion both on a purely morphological basis (the gland cells are cuboidal to triangular and contain a centrally located round nucleus) and after histochemical evaluation (the foveolar and pit cells contain a large amount of mucin, whereas those of the adult mucosa contain a long time contain only a small amount of mostly acidic mucins). We used the term CM

References

Author’s reply
We would like to thank Dr Chandrasoma for his informative reading and kind comments on our work published in Gut. He has also provided the readers with an admirable synthesis of the most recent research on the development of the different mucosal types in the gastro-oesophageal junction region. By means of this letter, we want to reflect on some of his comments.

The quintessence of Dr Chandrasoma’s vision on cardiac mucosa (CM) is that it is not a normal structure but develops through metaplasia in the context of gastro-oesophageal reflux disease. The presence of a small length of CM in many “normal” adults could be the result of asymptomatic low level reflux. According to his belief in “non-committed non-glandular late fetal forgoing epithelium” (which we call CM in our study) will develop into either oesophageal squamous epithelium or gastric mucosa with parietal cell containing glands. The necessary corollary of his theory is that there can be no such thing as a normal CM. He also puts forward the notion that the presence of CM in some infants might be due to deviant differentiation of the uncommitted epithelium in the context of reflux or other trauma such as nasogastric intubation. Even if this hypothesis is correct, we think that other possibilities should be considered. One possible situation could be the persistence of the uncommitted epithelium with development of a sort of heterotopic CM (analogous to the heterotopic fundic-type mucosa described in the upper third of the oesophagus). Clearly, more research is necessary.

Obviously, our work is not completely representative of the development of the gastro-oesophageal region throughout gestation. Notably, we need extra specimens from third trimester fetuses. At this moment we are gathering this material for future research. As Dr Chandrasoma himself says, the most important reason for the divergent conclusions of his work and ours are the terminology and interpretation of the data. What we call CM, in Dr Chandrasoma’s opinion, is uncommitted epithelium devoid of glands. He specifically warns against applying the designation “gland” to the tangentially cut tortuous ends of the foveolar pits (our fig 2 and fig 4). We believe glands are present in these illustrations. We formed this conclusion both on a purely morphological basis (the gland cells are cuboidal to triangular and contain a centrally located round nucleus) and after histochemical evaluation (the foveolar and pit cells contain a large amount of mucin, whereas those of the adult mucosa contain a long time contain only a small amount of mostly acidic mucins). We used the term CM...
for this zone interposed between squamous and fundic mucosa because of its morphological analogy with adult CM (whether normal or abnormal). Its principal characteristic is the presence of mucus producing glands devoid of parietal cells. We stated that CM develops during gestation and is present at birth. We do not know what happens with this cell type in adults and children. We cannot comment on the identity of adult CM: has it always been there or did it develop through metaplasia? To prove or disprove Dr Chandrasoma’s theory, evidently much further research has to be done.

G De Hertogh, P Van Eycken, K Geboes
Dienst Pathologische Onthelduinde, UZ Leuven,
Leuven, Belgium

Correspondence to: Dr G De Hertogh, UZ St-Rafaël
Minderbroedersstraat 12, Leuven 3000, Belgium.
gert.dehertogh@haz.kuleuven.ac.be

Helicobacter pylori infection in
Africa and Europe: enigma of host genetics

Helicobacter pylori infection is one of the most common bacterial infections. The prevalence varies from 25–50% in developed countries to 70–90% in the third world.1 Despite improved treatment modalities, H pylori related gastrointestinal pathology, in common with gastritis, peptic ulcers and consecutive bleeding events, gastric MALT lymphoma, or carcinoma, remains a major burden on Western health systems. In the USA, approximately four million people have active peptic ulcers and about 350,000 new cases are diagnosed each year. Four times as many duodenal ulcers as gastric ulcers are diagnosed.2 Epidemiological evidence suggests that both infection with H pylori and the consecutive development of clinically relevant pathology are influenced by genetic predisposition as only a fraction of exposed individuals develop infection and likewise a fraction of infected individuals develop ulcers or even gastric cancer.3,4 Thye et al used H pylori reactive serum immunoglobulin G as a marker of H pylori infection in Senegalese siblings and provided for the first time concrete statistical evidence for a genetic predisposition to H pylori infection. The authors reported an association between IFNGR1 polymorphisms and high antibody concentrations.5 Inclusion of the three variants (H318P, L450P, N56T) in the linkage analysis increased the LOD score to 4.2. The two African amino acid exchange variants, H318P and L450P, were not found in 100 unselected Europeans.6

Immediately, the question arises of whether variation in the interferon γ receptor 1 (IFNGR1) locus is related to H pylori infection or pathology in Caucasian populations We genotyped two polymorphisms at the IFNGR1 locus (rs688914, rs11914) in 344 H pylori infected individuals undergoing upper gastrointestinal endoscopy from northern Germany and 311 healthy blood donors. H pylori infection was tested by rapid urease test from a gastric biopsy or histology. Patients were grouped according to the severity of the mucosal inflammation, ranging from mild inflammation such as gastritis or duodennitis, to erosions and ulcer disease. Polymorphisms were selected from the Applied Biosystems “Assay on Demand” service (https://store.appliedbiosystems.com) and genotyped by Taqman using standard protocols. Because both polymorphisms were non-functional single nucleotide polymorphisms (rs11914: synonymous T/G exchange in exon 1, frequency in blood donors 13.5%; rs688914: C/T exchange about 6.5 kb downstream of the transcriptional start site, frequency in blood donors 31.3%), a haplotype case control analysis was performed using Hapmap7 to assess the association of the locus with the respective phenotypes. The markers exhibited a low degree of linkage disequilibrium (LD) (D’ = 0.174) yielding a highly informative haplotype analysis of the locus (frequencies in normal controls: TC 0.386; TT 0.100; GC 0.279; GT 0.035). No significant association with infection status or severity of H pylori related inflammation was found (table 1).

We conclude that INFGR1 is unlikely to be involved in the aetiology of H pylori infection or the development of clinical sequelae in German Caucasians. This may be due to aetiological differences between African and Caucasian individuals, as suggested pathophysiologically by Mitchell et al, who demonstrated major differences in the IgG subclass response to H pylori infection in the first and third world.8 In relation to clinical disease manifestations, the INFGR1 locus may affect antibody concentrations but not the clinical course of H pylori infection in Caucasians. Alternatively, other immunoregulatory genes in the vicinity of the INFGR1 locus such as the interleukin 20 receptor (200 kb distance) or MAP kinases 5 (600 kb distance) could harbour the causative variants. High density LD mapping of the locus is required to unravel the causative genetic variants in both African and Caucasian populations. Our data support the hypothesis that the genetic diversity of the host immune system may contribute to the differences in H pylori clinical phenotype and outcome in African and Caucasian populations.

S Hellming, J Hampe, S Schreiber
Department of General Internal Medicine, Christian- Albrechts-University Kiel, Germany

Correspondence to: Professor S Schreiber, Klinik für Allgemeine Innere Medizin, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Haus Leopoldstraße 12, 24105 Kiel, Germany; s.schreiber@muco.de

References

Platelet activation in patients with irritative bowel syndrome may reflect a subclinical inflammatory response

We read the recent article by Houghton et al and found the results very interesting (Gut 2003;52:663–70). Their observations included higher platelet concentrations of 5-hydroxytryptamine among patients with diarrhoea predominant irritable bowel syndrome (dIBS) compared with controls. It is interesting that a small but significant subgroup of IBS patients report onset of their symptoms after an episode of acute gastroenteritis and a role of subclinical inflammatory aetiology has been suggested for the condition.9 The role of platelets in various inflammatory conditions has previously been demonstrated but their importance in IBS remains largely unknown.10,11 We recently looked at the possibility of platelet activation in IBS patients by determining surface expression of the activation markers at baseline and after stimulation. Stimulation involved the use of thrombin receptor activating peptide (TRAP), activation markers P-selectin (CD62) and glycoprotein 53 (CD63), and glycoprotein (GP) receptors GPIb-IX and GPIb/IIIa, using whole blood blood flow cytometric analysis (Becton Dickenson Flow Cytometer).11,12 Twenty consecutive IBS patients (18 females), mean age 29 years (20–62), fulfilling the Rome II criteria (90% d-IBS) and 15 healthy controls (11 females), mean age 28 years (22–49), were included. Raised inflammatory markers, previous bowel dis-

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Haplotype analysis of infection status and clinical manifestation of Helicobacter pylori infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparison groups</td>
<td>n (groups)</td>
</tr>
<tr>
<td>Infection status (normal controls versus all H pylori positive patients)</td>
<td>311</td>
</tr>
<tr>
<td>Moderate versus mild pathology in H pylori infected patients</td>
<td>66</td>
</tr>
<tr>
<td>(gastric/duodenal erosions versus no pathology or gastritis/duodeni)</td>
<td></td>
</tr>
<tr>
<td>Severe versus mild pathology in H pylori infected patients</td>
<td>112</td>
</tr>
<tr>
<td>(gastric/duodenal ulcers versus no pathology or gastritis/duodeni)</td>
<td></td>
</tr>
</tbody>
</table>

The table shows the comparative frequencies of the INFGR1 haplotype described above. Sensitivity to H pylori infection was tested by comparison of all H pylori positive patients (n = all subgroups: 66:112:166 = 344) against normal controls (top row). Genetic predisposition for communicable infections was tested by comparison of patients with H pylori infection (gastric or duodenal erosions, n = 66) and severe pathology (gastric or duodenal ulcers n = 112) against patients with mild or no pathology grouped together (no pathology, gastritis, or duodeni, n = 166).
ease or surgery, diverticulosis, and current or recent (past four weeks) use of non-steroidal anti-inflammatory drugs were exclusion criteria. Standard venepuncture precautions were observed for sample collection and final analysis. A fluorescent isothiocyanate (FITC) conjugated GPIb specific antibody was used to gate around the platelet population and list mode data on 10,000 platelets acquired. Mean fluorescence intensity (MFI) was used to quantify FITC labelled GPIb/IIIa and GPIb-IX specific antibody binding. Binding of P-selectin and GP53 to a phycoerythrin labelled monoclonal antibody was expressed as the percentage of platelets positive for that antibody (% fluorescence). We tested varying strengths of TRAP, ranging from 110 to 223 mM (concentration used for reactivity of circulating platelets at a concentration of 223 mM (concentration used for activation studies). Differences between groups (p) were assessed using the Mann-Whitney U test for unpaired data. All analyses were performed using the Minitab statistical software and SPSS for windows (10.0.5).

Baseline expression of P-selectin was significantly increased in the IBS group (median 5.9 (interquartile range (IQR) 4.4 – 8.9)) compared with healthy controls (median 4.1 (IQR 3.2 – 5.9)) (p = 0.03), all values representing per cent expression. Baseline expression of GP53 was higher in the IBS group (median 3.0 (IQR 1.9-4.0)) compared with normal controls (median 2.3 (IQR 1.9–2.8)) but failed to reach clinical significance. TRAP stimulation resulted in increased expression of P-selectin and GP53 in both groups. Glycoprotein reactivity post stimulation was significantly lower in the IBS group compared with normal controls (p<0.05).

The numbers of GPIb/IIIa and GPIb-IX receptor sites on the platelet surface for each group were calculated using a calibration curve where MFI and the corresponding number of antibody sites of multiple bead populations were plotted using a log log scale. The results in the two groups were comparable.

In IBS patients with normal routine inflammatory markers, we demonstrated a significant increase in surface expression of both P-selectin and GP53. The observed changes in baseline and reactive expression of platelet activation markers may support the theory of an ongoing subclinical inflammatory process in IBS. Reduced glycoprotein reactivity following TRAP stimulation in IBS may possibly signify a continuous low level platelet activation and degranulation with consequent platelet “exhaustion” and reduced expression of antigens. Precise interpretation of our results remains unclear due to the small number of included patients. Future studies involving a wider IBS population with possible subdivision based on various disease characteristics, including determination of the possible disease triggering event, particularly a past history of gastroenteritis, may help to further clarify these observations.

CORRECTIONS

Two errors have been noted in the paper by CJ Hawkey et al in the June issue (Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut 2003;52:820–6). On page 822, the lower 95% CI for the difference between rofecoxib and placebo (4.05), is given as 93.37 rather than 3.37. Also, in the key to fig 2, the dose of rofecoxib is given as 500 mg instead of 50 mg.

In the letter by Siveke et al (Gut 2003; 52:1531) the author list was ordered incorrectly as JT Siveke, C Folwaczny, and C Herberhold. The correct order for the listing of authors should have been JT Siveke, C Herberhold and C Folwaczny. This was due to a technical error for which the journal apologises.

NOTICES

British Society of Gastroenterology Paul Brown Travel Fellowships

The Paul Brown Travel Fellowships are awarded by the Endoscopy Committee of the BSG. They are intended to assist trainee gastroenterologists and established consultants in visits to units outside the United Kingdom for specialist experience and training in endoscopy.

Specialist registrars who have not achieved their CCST are expected to have the approval of their Postgraduate Dean and their Regional Training Director when they apply for a Travel Fellowship. Applicants are expected to provide confirmation that they have been accepted for training in the unit that they wish to visit.

Successful applicants will be expected to provide a brief written report to the Endoscopy Committee of the outcome of their visit.

Application forms are available from the British Society of Gastroenterology Office, 3 St Andrew’s Place, London NWI 4LB. Email: bsg@mailbox.ulc.ac.uk

Hong Kong-Shanghai International Liver Congress 2004

This conference will be held on 14–17 February 2004 in Hong Kong. The topic of the conference is “Liver Diseases in the Post-Genomic Era”. Further details: Ms Kristie Leung, Room 102–105 School of General Nursing, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong. Tel: +852 2818 4300/8101 2442; fax: +852 2818 4000; email: kristieleung@hepa2004.org; website: www.hepa2004.org

PET/CT and SPECT/CT Imaging in Medical, Radiation, Surgical and Nuclear Oncology

This continuing medical education programme will take place on 19–20 March 2004 at Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Further details: Office of Continuing Medical Education, Johns Hopkins University School of Medicine, Turner 20, 720 Rutland Avenue, Baltimore, Maryland 21205-2195. Tel: +1 410 955 2959; fax: +1 410 955 0807; email: cmenet@jhmi.edu; website: www.hopkinscmc.org

93rd Annual Meeting of the European Association for the Study of the Liver

This meeting will be held on 15–19 April 2004 in Berlin, Germany. Further details: Secretariat, C.Keens International, 17 rue du Cendrier, PO Box 1726, CH-1211 Geneva, Switzerland. Tel: +41 22 908 0488; fax: +41 22 732 2850; email: info@easl.ch; website: www.easl.ch/easl2004

• Deadline for receipt of abstracts: 16 November 2003
• Deadline for early registration 10 February 2004

Second Sheffield Multi-Disciplinary Colorectal Meeting

There will be a multi-disciplinary symposium for surgeons, physicians, radiologists and specialist nurses on 9 January 2004. The faculty includes: Wendy Atkin—St Mark’s (London), Professor Jonathan Rhodes—Univeristy of Liverpool, Professor John Scholefield—Nottingham, Dr S Taylor—St Mark’s Hospital, Mr Andrew Shorthouse—Sheffield, Dr Stewart Riley—Sheffield, and Karen Smith—Nurse Endoscopist at Sheffield. The Second Sheffield Multi-Disciplinary Colorectal Meeting takes place between 10am and 5pm at the Postgraduate Centre, Northern General Hospital, Sheffield. The registration fee is £25. For further details, please contact: Anne Smedley, Secretary to Mr AJ Shorthouse, Royal Hallamshire Hospital, Glossop Road, Sheffield, S19 2JF.

References

High magnification chromoscopic colonoscopy as a screening tool in acromegaly

D P Hurlstone, S S Cross, A J Lobo and D S Sanders

*Gut* 2003 52: 1797-1798
doi: 10.1136/gut.52.12.1797

Updated information and services can be found at:
http://gut.bmj.com/content/52/12/1797

These include:

**References**
This article cites 19 articles, 5 of which you can access for free at:
http://gut.bmj.com/content/52/12/1797#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/